Free Trial
NASDAQ:PYPD

PolyPid Q1 2025 Earnings Report

PolyPid logo
$2.79 -0.01 (-0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$2.76 -0.02 (-0.90%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PolyPid EPS Results

Actual EPS
N/A
Consensus EPS
-$0.74
Beat/Miss
N/A
One Year Ago EPS
N/A

PolyPid Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PolyPid Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

PolyPid Earnings Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
PolyPid management to meet with Oppenheimer
Barclays Reaffirms Their Hold Rating on PolyPid (PYPD)
See More PolyPid Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PolyPid? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PolyPid and other key companies, straight to your email.

About PolyPid

PolyPid (NASDAQ:PYPD), a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

View PolyPid Profile

More Earnings Resources from MarketBeat